Evidence map›Paper›PMID 30143206›Full record

ReviewAnalytica chimica acta2018

Early diagnosis of disease using microbead array technology: A review.

Sanam Foroutan Parsa, Atieh Vafajoo, Azin Rostami, Reza Salarian, Mohammad Rabiee, Navid Rabiee, Ghazal Rabiee, Mohammadreza Tahriri, Amir Yadegari, Daryoosh Vashaee and 2 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Analytica chimica acta, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Diagnostic applications of microsphere-based flow cytometry: A review.Experimental biology and medicine (Maywood, N.J.) · 2022
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sanam Foroutan ParsaBiomaterials Group, Faculty of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
Atieh VafajooBiomaterials Group, Faculty of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
Azin RostamiBiomaterials Group, Faculty of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
Reza SalarianBiomedical Engineering Department, Maziar University, Noor, Royan, Iran.
Mohammad RabieeBiomaterials Group, Faculty of Biomedical Engineering, Amirkabir University of Technology, Tehran, Iran.
Navid RabieeDepartment of Chemistry, Shahid Beheshti University, Tehran, Iran.
Ghazal RabieeDepartment of Chemistry, Shahid Beheshti University, Tehran, Iran.
Mohammadreza TahririMarquette University School of Dentistry, Milwaukee, WI 53233, USA. Electronic address: mohammadreza.tahriri@marquette.edu.
Amir YadegariMarquette University School of Dentistry, Milwaukee, WI 53233, USA.
Daryoosh VashaeeElectrical and Computer Engineering Department, North Carolina State University, Raleigh, NC 27606, USA.
Lobat TayebiMarquette University School of Dentistry, Milwaukee, WI 53233, USA; Biomaterials and Advanced Drug Delivery Laboratory, School of Medicine, Stanford University, Palo Alto, CA 94304, USA.
Michael R HamblinWellman Center for Photomedicine, Massachusetts General Hospital, Boston, MA 02114, USA; Department of Dermatology, Harvard Medical School, Boston, MA 02115, USA; Harvard-MIT Division of Health Sciences and Technology, Cambridge, MA 02139, USA. Electronic address: hamblin@helix.mgh.harvard.edu.

Funding

Photodynamic Therapy of Localized InfectionsR01AI050875 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2003 to 2017
$4.8M
Synergistic Photodynamic Therapy for Catherer-Associated Urinary Tract InfectionsR21AI121700 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI HAMBLIN, MICHAEL R · 2016 to 2017
$462k
NIAID NIH HHS R01 AI050875NIAID NIH HHS R21 AI121700
6 · The paper itself

Abstract

Early diagnosis of diseases (before they become advanced and incurable) is essential to reduce morbidity and mortality rates. With the advent of novel technologies in clinical laboratory diagnosis, microbead-based arrays have come to be recognized as an efficient approach, that demonstrates useful advantages over traditional assay methods for multiple disease-related biomarkers. Multiplexed microbead assays provide a robust, rapid, specific, and cost-effective approach for high-throughput and simultaneous screening of many different targets. Biomolecular binding interactions occur after applying a biological sample (such as blood plasma, saliva, cerebrospinal fluid etc.) containing the target analyte(s) to a set of microbeads with different ligand-specificities that have been coded in planar or suspension arrays. The ligand-receptor binding activity is tracked by optical signals generated by means of flow cytometry analysis in the case of suspension arrays, or by image processing devices in the case of planar arrays. In this review paper, we discuss diagnosis of cancer, neurological and infectious diseases by using optically-encoded microbead-based arrays (both multiplexed and single-analyte assays) as a reliable tool for detection and quantification of various analytes.

Indexed as

Early Detection of CancerFlow CytometryHumansMicrospheresNeoplasmsBiomarkerCancerEarly diagnosisInfectious diseaseMicrobead array applicationsMultiplexingNeurological disease

Identifiers

PMID30143206
PMCPMC6152944

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.